Loading news...
Guru Stock PicksLarry Robbins has made the following transactions:Add in MYGN by 7.71%Stock News Trump floats 10% cap on card APRs: President Trump proposed a o
Stock News DOJ subpoenas Fed chair spark backlash: Federal prosecutors served grand jury subpoenas to Jerome Powell over testimony on Fed HQ renovations, prompt
Quest Diagnostics Incorporated (DGX) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
SG Americas Securities LLC lessened its position in Quest Diagnostics Incorporated (NYSE: DGX) by 46.4% during the undefined quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 22,622 shares of the medical research company's stock after selling 19,597 shares during the period. SG
Allspring Global Investments Holdings LLC grew its stake in Quest Diagnostics Incorporated (NYSE: DGX) by 50.6% during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 15,775 shares of the medical research company's stock after acquiring an additional 5,297 shares during the quarter.
SECAUCUS, N.J., Jan. 8, 2026 /PRNewswire/ -- Quest Diagnostics Incorporated (NYSE: DGX), a leader in diagnostic information services, today announced that it will report fourth quarter and full year 2025 financial results on Tuesday, February 10, 2026, before the market opens.
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Quest Diagnostics (NYSE: DGX - Get Free Report) and Daxor (NASDAQ: DXR - Get Free Report) are both medical companies, but which is the better business? We will contrast the two companies based on the strength of their institutional ownership, analyst recommendations, profitability, valuation, earnings, risk and dividends. Analyst Ratings This is a summary of current ratings
SECAUCUS, N.J., Jan. 6, 2026 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX), a leading provider of diagnostic information services, today announced that data will be shared on circulating tumor DNA (ctDNA) minimal residual disease (MRD) testing during two poster presentations at the 2026 ASCO Gastrointestinal Cancers Symposium, being held January 8-10, 2026 in San Francisco, CA.
Quest also now provides comprehensive Collaborative Lab Solutions (Co-Lab) hospital lab management services for all 21 Corewell Health hospitals SOUTHFIELD, Mich. and GRAND RAPIDS, Mich.
SteelPeak Wealth LLC decreased its stake in shares of Quest Diagnostics Incorporated (NYSE: DGX) by 91.6% during the undefined quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 1,252 shares of the medical research company's stock after selling 13,705 shares during the
Braun Stacey Associates Inc. increased its position in shares of Quest Diagnostics Incorporated (NYSE: DGX) by 13.5% during the third quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 154,369 shares of the medical research company's stock after buying an additional 18,417 shares during the quarter.
Quest Diagnostics (DGX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Copeland Capital Management LLC lowered its position in Quest Diagnostics Incorporated (NYSE: DGX) by 4.5% in the undefined quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 168,375 shares of the medical research company's stock after selling 7,889 shares
Assenagon Asset Management S.A. decreased its position in shares of Quest Diagnostics Incorporated (NYSE: DGX) by 73.2% during the third quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 5,588 shares of the medical research company's stock after selling 15,248 shares during the quarter. Assenagon
DGX banks on acquisitions, advanced diagnostics and cost discipline, even as debt levels and macro pressures pose risks.
Here is how Quest Diagnostics (DGX) and Elicio Therapeutics (ELTX) have performed compared to their sector so far this year.
Thrivent Financial for Lutherans boosted its position in Quest Diagnostics Incorporated (NYSE: DGX) by 88.6% during the second quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 24,167 shares of the medical research company's stock after buying an additional 11,351 shares during the quarter. Thrivent
Corient Private Wealth LLC reduced its holdings in Quest Diagnostics Incorporated (NYSE: DGX) by 27.1% during the undefined quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 25,005 shares of the medical research company's stock after selling 9,292 shares during the period. Corient Private Wealth